Ainos (AIMD) Issues Mid-Year Business Update Letter to Shareholders

Go back to Ainos (AIMD) Issues Mid-Year Business Update Letter to Shareholders

Ainos Issues Mid-Year Business Update Letter to Shareholders

June 27, 2023 8:32 AM EDT

Company ramping up marketing of VELDONA Pet and aiming to complete clinical trials in Taiwan of its flagship AI Nose-powered POCT by the end of 2023

Ainos sees VELDONA Pet and AI Nose-powered POCT as key drivers in transforming the company

SAN DIEGO, CA / ACCESSWIRE / June 27, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, is pleased to provide a business update letter to shareholders from Ainos' Chairman of the Board,... More